Skip to content
WealthTicker

Compare

NAVs as of 20 Aug 2026

Mahindra Manulife Balanced Advantage FundDirect1 of 4 funds

Add a second fund to compare. Until then every figure below is shown against the Dynamic Asset Allocation or Balanced Advantage median (37 funds), which is the only comparison one fund can support.

Growth of ₹100 (rebased over the selected window)

Common period 03 Jan 202220 Aug 2026, limited by Mahindra Manulife Balanced Advantage Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.

View as table
Growth of ₹100, sampled across the common period
DateMahindra Manulife Balanced Advantage FundNifty 50
03 Jan 2022₹100.00₹100.00
24 May 2022₹96.46₹91.49
12 Oct 2022₹101.68₹97.15
02 Mar 2023₹101.37₹98.28
20 Jul 2023₹114.41₹113.35
08 Dec 2023₹123.53₹118.97
27 Apr 2024₹138.06₹127.20
15 Sep 2024₹150.93₹143.86
03 Feb 2025₹144.68₹132.54
24 Jun 2025₹153.16₹142.09
11 Nov 2025₹157.41₹145.78
01 Apr 2026₹145.90₹128.67
20 Aug 2026₹163.14₹137.48
Mahindra Manulife Balanced Advantage Fund compared on return, risk, benchmark-relative, cost and portfolio metrics, against the Dynamic Asset Allocation or Balanced Advantage median.
Metric
Mahindra Manulife · Direct
NAV ₹16.33
High risk
★★★★☆
Category median
Dynamic Asset Allocation or Balanced Advantage · 37 funds
+6.16%+4.48%
+12.57%+11.02%
+10.08%
+10.76%
+11.16%+9.91%
+11.34%
+14.24%+12.11%
+11.73%
+11.91%
Risk
10.14%8.34%
0.600.52
0.800.72
-9.77%-15.25%
Nifty 50
+4.02%+2.88%
0.690.62
82.2%73.8%
46.5%43.9%
0.85%1.04%
₹886.08Cr₹2,076Cr
Up to 1.00%
None
₹500
₹1.00K
104%185%
Rahul Pal · 4.6y
03 Jan 2022
59
22.7%
4.2%

Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.